Major Bleeding in Patients With Coronary or Peripheral Rivaroxaban Plus Aspirin

Journal of the American College of Cardiology

74, 1519-1528

DOI: 10.1016/j.jacc.2019.07.065

Citation Report

#	Article	IF	Citations
1	Major Bleeding With Rivaroxaban and Aspirin. Reactions Weekly, 2019, 1772, 12.	0.0	0
2	Is Bleeding Always Bad?: Bad Boy Bleeding. Journal of the American College of Cardiology, 2019, 74, 1529-1531.	12.0	1
3	The COMPASS Trial: Practical Considerations for Application After Coronary Artery Bypass Surgery. Current Opinion in Cardiology, 2020, 35, 583.	2.2	1
4	Rivaroxaban for the Prevention of Major Adverse Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease. Future Cardiology, 2020, 16, 597-611.	1.2	2
5	Xarelto Plus Acetylsalicylic Acid: Treatment Patterns and Outcomes in Patients With Atherosclerosis (XATOA): Rationale and Design of a Prospective Registry Study to Assess Rivaroxaban 2.5 mg Twice Daily Plus Aspirin for Prevention of Atherothrombotic Events in Coronary Artery Disease, Peripheral Artery Disease, or Both. American Heart Journal, 2020, 222, 166-173.	3.3	24
6	Rivaroxaban: A Review for Secondary CV Prevention in CAD and PAD. Drugs, 2020, 80, 1465-1475.	15.5	13
7	The COMPASS Trial. Circulation, 2020, 142, 40-48.	24.6	157
8	Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome. CJC Open, 2020, 2, 402-415.	1.8	8
9	Cancer Unmasked by Bleeding During Anticoagulant Therapy: When a Problem May Become an Opportunity. European Heart Journal, 2022, 43, e45-e47.	14.7	2
10	The Future of Aspirin Therapy in Cardiovascular Disease. American Journal of Cardiology, 2021, 144, S40-S47.	2.4	5
11	Methods of Decreasing the Risk of Repeat Interventions in Patients After Arterial Revascularization. Angiologiia I Sosudistaia Khirurgiia = Angiology and Vascular Surgery, 2021, 27, 169-175.	0.2	0
12	Low Dose Rivaroxaban for Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 2021, 11, 608247.	5.3	9
13	Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction. Journal of the American Heart Association, 2021, 10, e017008.	5.8	25
14	Cardiovascular Consequences of Discontinuing Low-Dose Rivaroxaban in People With Chronic Coronary or Peripheral Artery Disease. Heart, 2021, 107, 1130-1137.	4.9	11
15	Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. Journal of the American College of Cardiology, 2021, 78, 14-23.	12.0	52
16	Antithrombotische Therapie Bei Diabetes Mellitus. Diabetologe, 2021, 17, 825-833.	0.2	0
17	Updated Antithrombotic Strategies to Reduce the Burden of Cardiovascular Recurrences in Patients With Chronic Coronary Syndrome. Biomedicine and Pharmacotherapy, 2021, 140, 111783.	9.8	3
18	Combination Anticoagulant or P2Y12 Inhibitor With Low-Dose Aspirin Versus Low-Dose Aspirin Alone in Patients at Risk or With Documented Coronary And/Or Peripheral Artery Disease. Current Medical Research and Opinion, 2022, 38, 27-34.	2.9	2

#	Article	IF	Citations
19	Coronary Artery Disease With a High Risk of Complications: How to Identify Such Patients and Choose Management Tactics?. Rational Pharmacotherapy in Cardiology, 2020, 16, 465-473.	0.6	0
20	Clinical Implications of the Log Linear Association Between LDL-C Lowering and Cardiovascular Risk Reduction: Greatest Benefits When LDL-C >100 mg/Dl. PLoS ONE, 2020, 15, e0240166.	3.2	8
21	State-of-the-Art Mini Review: Dual-Pathway Inhibition to Reduce Arterial and Venous Thromboembolism. Thrombosis and Haemostasis, 2022, 122, 1279-1287.	4.6	17
22	Long-Term Treatment With the Combination of Rivaroxaban and Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS Trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 786-795.	5.0	20
23	Clinical Features and Posttreatment Monitoring of Dogs Administered Rivaroxaban (2018–2020): 19 Cases. Journal of Veterinary Emergency and Critical Care, 2022, 32, 629-636.	1.4	10
24	Antithrombotische Therapie Bei Diabetes Mellitus. Die Kardiologie, 2022, 16, 253-262.	1.4	0
25	Efficacy and Safety of New Oral Anticoagulants Combined With Antiplatelet Drugs in the Treatment of Coronary Heart Disease: Systematic Evaluation and Meta-Analysis. Annals of Noninvasive Electrocardiology, 2022, 27, e12977.	0.9	3
26	Dual Pathway Inhibition in Patients With Atherosclerotic Disease: Pharmacodynamic Considerations and Clinical Implications. Expert Review of Clinical Pharmacology, 2023, 16, 27-38.	3.6	18
27	Bleeding Risk in Patients With Peripheral Arterial Disease. Life, 2023, 13, 47.	4.3	10
28	Low-Dose Rivaroxaban: Can Cardiovascular Events Be Reduced?. European Heart Journal Supplements, 2023, 25, C20-C26.	2.9	4
29	Switching From Dual Antiplatelet Therapy With Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition With Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study. Thrombosis and Haemostasis, 2024, 124, 263-273.	4.6	9
30	External Validation of the OAC3-PAD Bleeding Score in a Nationwide Population of Patients Undergoing Invasive Treatment for Peripheral Arterial Disease. European Journal of Vascular and Endovascular Surgery, 2024, 67, 621-629.	3.2	5
31	Bleeding Risk Prediction in Patients Treated With Antithrombotic Drugs According to the Anatomic Site of Bleeding, Indication for Treatment, and Time Since Treatment Initiation. TH Open, 2024, 08, e121-e131.	1.8	4
32	Real-World Bleeding Risk of Anticoagulant and Nonsteroidal Anti-Inflammatory Drugs Combotherapy Versus Anticoagulant Monotherapy. Gut and Liver, 2024, 18, 824-833.	3.5	7
33	Dual Antithrombotic Therapy Versus Anticoagulant Monotherapy for Major Adverse Limb Events in Patients With Concomitant Lower Extremity Arterial Disease and Atrial Fibrillation: A Propensity Score Weighted Analysis. European Journal of Vascular and Endovascular Surgery, 2024, 68, 498-507.	3.2	5
34	Characteristics of the Russian Population of Patients With Coronary Artery Disease or Peripheral Artery Disease in the XATOA Registry. Rational Pharmacotherapy in Cardiology, 2024, 20, 241-248.	0.6	0
35	Dual Pathway Inhibition in Patients With Peripheral Artery Disease in Germany. Vasa - European Journal of Vascular Medicine, 2025, 54, 142-149.	2.7	1
36	. Advances in Clinical Medicine, 2025, 15, 1145.	0.1	2

#	Article	IF	Citations
37	Dual Pathway Inhibition in Patients With Coronary Artery Disease (CAD) in Clinical Practice in Germany: Results From the German CAD Subgroup of the XATOA Registry. Clinical Research in Cardiology, 2025, .	3.9	0
38	Validation of High Ischemic and Bleeding Risk Criteria of European Guidelines in Peripheral Arterial Disease. JACC Asia, 2025, 5, 744-754.	3.7	4
39	Aspirin Plus Rivaroxaban vs Aspirin Alone: Improvement of Claudication, Limb Pain and Ankle-Brachial Index in Diabetic Peripheral Arterial Disease (PAD) Before Revascularization: A Clinical Randomized Trial. International Cardiovascular Research Journal, 2025, 19, e154736.	0.4	1
40	Anticoagulation in Peripheral Artery Disease: Scoping Review With ❄SAIMSARA. , 2026, .		0
41	Peripheral Artery Disease Treatment: Scoping Review With ❄SAIMSARA. , 2026, .		0
42	Preliminary Clinical Observation of a Novel Anticoagulation Regimen in the Acute Phase of Thromboangiitis Obliterans (Buerger's Disease). Asian Journal of Surgery, 2026, .	0.7	0